Home › Funds › KVP Capital Advisors, LP › EWTX
KVP Capital Advisors, LP position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
KVP Capital Advisors, LP reported holding 133,000 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$5.4M, representing 3.97% of its reported portfolio and ranking #9 among its reported holdings. KVP Capital Advisors, LP has disclosed EWTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How KVP Capital Advisors, LP's EWTX position evolved
KVP Capital Advisors, LP first disclosed a stake in EWTX in Q4 2025 at 133,000 shares (US$3.3M). The position peaked in Q2 2026 at 133,000 shares, worth US$5.4M. Across 3 filings, KVP Capital Advisors, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 133,000 shares valued at US$5.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 133.00K | $3.30M | New |
| Q1 2026 | 133.00K | $4.19M | Hold |
| Q2 2026 | 133.00K | $5.40M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- ORBIMED ADVISORS LLC 15.52M sh · $630.52M · Q2 2026
- Paradigm Biocapital Advisors LP 10.22M sh · $415.05M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 8.39M sh · $341.00M · Q2 2026
- Novo Holdings A/S 5.35M sh · $217.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.73M sh · $192.12M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.37M sh · $177.71M · Q2 2026
- BAKER BROS. ADVISORS LP 3.70M sh · $150.40M · Q2 2026
- Siren, L.L.C. 3.18M sh · $129.39M · Q2 2026
- Cormorant Asset Management, LP 2.51M sh · $101.98M · Q2 2026
- Integral Health Asset Management, LLC 2.00M sh · $81.26M · Q2 2026
- BRAIDWELL LP 2.00M sh · $81.14M · Q2 2026
- MPM BioImpact LLC 1.62M sh · $65.85M · Q2 2026
More on KVP Capital Advisors, LP
FAQ
How long has KVP Capital Advisors, LP held EWTX?
KVP Capital Advisors, LP has disclosed EWTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is KVP Capital Advisors, LP's current position in EWTX?
As of Q2 2026, KVP Capital Advisors, LP holds 133.00K shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $5.40M, representing 3.97% of its reported portfolio and ranking #9.
Has KVP Capital Advisors, LP been buying or selling EWTX?
In the latest 13F filing (Q2 2026), KVP Capital Advisors, LP held unchanged its position in EWTX. The position peaked in Q2 2026 at 133.00K shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.